Kodiak Sciences’ (KOD) “Buy” Rating Reaffirmed at Chardan Capital

Kodiak Sciences (NYSE:KOD)‘s stock had its “buy” rating reissued by equities researchers at Chardan Capital in a report released on Monday, AnalystRatings.com reports. They presently have a $40.00 price objective on the stock. Chardan Capital’s target price indicates a potential downside of 18.70% from the stock’s current price.

Separately, Zacks Investment Research lowered Kodiak Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday, October 29th.

Shares of KOD stock opened at $49.20 on Monday. Kodiak Sciences has a 52-week low of $5.65 and a 52-week high of $72.97. The firm’s 50 day moving average price is $24.70 and its two-hundred day moving average price is $15.55.

Kodiak Sciences (NYSE:KOD) last issued its earnings results on Tuesday, November 12th. The company reported ($0.33) EPS for the quarter, meeting the consensus estimate of ($0.33).

A number of institutional investors and hedge funds have recently modified their holdings of KOD. JPMorgan Chase & Co. grew its position in shares of Kodiak Sciences by 179.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 6,476 shares of the company’s stock worth $73,000 after buying an additional 4,161 shares during the period. Marshall Wace North America L.P. bought a new stake in shares of Kodiak Sciences in the 1st quarter valued at about $73,000. Hillsdale Investment Management Inc. bought a new stake in shares of Kodiak Sciences in the 2nd quarter valued at about $99,000. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Kodiak Sciences in the 2nd quarter valued at approximately $122,000. Finally, Metropolitan Life Insurance Co NY acquired a new stake in shares of Kodiak Sciences in the 3rd quarter valued at approximately $131,000.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy.

Recommended Story: Technical Indicators – What is a Golden Cross?

Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.